Background: Recently, the relationship between increased level of inflammatory mediators and occurrence of left ventricular failure in patients with kidney disease has been suggested. The present study attempted to assess relationship between inflammatory mediators and occurrence of left ventricular failure in patients with chronic kidney disease. Materials and Methods: This cross-sectional study was performed at Noor and Hazrat Aliasghar hospital in Isfahan between September 2012 to September 2013 on patients aged >19 years that referred for following their chronic kidney disease. Serum level of inflammatory parameters including C-reactive protein (CRP) and Interleukin-6 (IL-6) was measured using spectrophotometer. All patients were also assessed using M-mode echocardiography to determine left ventricular ejection fraction (LVEF). Results: The group with significant reduced LVEF showed lower GFR when compared to the normal LVEF group (40.73 ± 20.61% versus 44.43 ± 17.98%, P = 0.032). Comparing GFR across the three groups with normal LVEF (>55%), with mild LV dysfunction (LVEF: 45 -55) those with significant LV dysfunction (LVEF < 45%) showed significantly lower GFR level in latter group compared with normal LVEF and mild LV dysfunction group (P = 0.026). Although the level of serum CRP was significantly higher in patients with significant left ventricular failure than other groups (P = 0.018). Conclusion: Inflammatory processes can potentially affect left ventricular function in patients with chronic kidney disease. In this regard, increased level of CRP may be a main factor for predicting severity of left ventricular failure in these patients.
Introduction
Nowadays, chronic kidney disease is one of the main causes of disability responsible for a high cost burden on healthcare systems in each society. This health problem not only has an increasing trend in most developed and developing countries, because of the necessity for prolonged dialysis or needing kidney transplantation, a considerable part of health budgets is being spent for managing and controlling this phenomenon. [1, 2] One of the main consequences of chronic kidney disease caused by progression of cardiovascular disease is left ventricular failure that affects about 75 percent of the patients in early stages of dialysis. [3, 4] The severity of left ventricular failure is directly associated with the level of renal failure progression. [5] Moreover, left ventricular failure has been introduced as an independent factor for predicting high cardiovascular-related mortality in chronic kidney disease patients. Besides, inflammatory processes have been well identified as the main background for both cardiovascular and kidney dysfunction leading left ventricular hypertrophy and heart failure.
[6] Numerous studies have recently shown strong evidences on association of increased level of inflammatory cell and mediators with different phases of coronary artery diseases. It has been also revealed that increased level of inflammatory biomarkers including c-reactive protein (CRP), tumor necrotizing factor (TNF-α), and interleukin-6 (IL-6) can be associated with increased risk for heart failure, even in those without any previous evidences of coronary heart diseases. [7] [8] [9] In addition, inflammatory processes have been shown to be associated with deterioration of kidney dysfunction that can be accompanied with uremia, increased level of stress oxidative, protein loss, and increased susceptibility to infections. In this regard, the increase of CRP in patients undergoing hemodialysis is a powerful
